Investec has changed its rating from “sell” to “hold”. It said the stock appeared overpriced following a slow return on earnings recovery. The stock now has a target price of 255p
Shore Capital has retained its “sell” rating on the firm after Capita lost a contract from the Criminal Records Bureau, previously delivering £60m of revenue a year. Sell at 762p.
Panmure Gordon has downgraded AstraZeneca from “buy” to “hold” after the firm cancelled a share buy back – opening the door for an acquisition by the firm. Sell at 2,925p.